Evommune, Inc.
NYSE:EVMNBiotechnology
-$0.17 today
- Market cap
- $284.49M
- Beta
- 0.10
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$2.26
Volume 0.60M
Average 0.38M
EVMN Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Evommune, Inc.NYSE: EVMN
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $349K fell 7.4% year over year. Sequentially, it rose 7.1% from the prior quarter.
Context
- Depreciation & amortization amounted to 10.7% of revenue in FY2025, down 7.7 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 2 fiscal years.
- FY2025 was the highest annual figure in the 3 fiscal years shown.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 1.39M USD
- Year-over-year change
- +7.9%
- 2-year CAGR
- +17.9%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.39M | +7.9% |
| FY2024 | 2024-12-31 | 1.29M | +28.7% |
| FY2023 | 2023-12-31 | 1M | — |
Depreciation & Amortization vs competitors
How EVMN compares with its peers on the latest reported figures
- EVMN's LTM Mar 2026 depreciation & amortization of $1.36M is the 9th largest of the 10 companies compared; the peer median is $6.75M.
- Depreciation & amortization amounts to 13.6% of revenue for EVMN, versus a peer median of 8.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
FTREFortrea Holdings Inc. | LTM Jun 2026 | $78.3M | -3.5% | -5.9% | 2.9% |
| LTM Jun 2026 | $34.32M | -1.7% | -8.0% | 11.8% | |
| LTM Mar 2026 | $23.65M | +1.1% | +6.0% | 81.8% | |
| LTM Sep 2026 | $9.03M | -29.4% | -2.5% | 3.4% | |
| LTM Mar 2026 | $6.75M | +171.1% | -20.0% | 8.6% | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $2.71M | +9.6% | +30.9% | — |
| LTM Mar 2026 | $2.56M | -49.9% | — | 1.7% | |
| LTM Mar 2026 | $2.45M | +41.2% | -1.9% | 32.1% | |
EVMNEvommune, Inc. | LTM Mar 2026 | $1.36M | — | — | 13.6% |
CLYMClimb Bio, Inc. | LTM Mar 2026 | $97K | — | — | — |
| Peer median (excluding EVMN) | $6.75M | -0.3% | -2.5% | 8.6% | |
Competitors are the stored peer set for EVMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Net Income | (34.05M) | (66.81M) | (68.87M) |
| Depreciation & Amortization | 1M | 1.29M | 1.39M |
| Deferred Income Tax | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 |
| Change in Working Capital | 3.34M | 7.42M | (4.12M) |
| Accounts Receivables | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 |
| Accounts Payables | 125K | 6.51M | (837K) |
| Other Working Capital | 3.22M | 918K | (3.28M) |
| Other Non-Cash Items | (261K) | (98K) | (4.84M) |
| Operating Cash Flow | (29.97M) | (58.2M) | (76.44M) |
| Capital Expenditures | (118K) | (88K) | (235K) |
| Acquisitions (Net) | 0 | 0 | 0 |
| Purchases of Investments | (91.31M) | (90.26M) | (199.17M) |
| Sales of Investments | 43M | 86.35M | 84.1M |
| Other Investing Activities | 0 | 0 | 0 |
| Investing Cash Flow | (48.43M) | (3.99M) | (115.31M) |
| Debt Repayment | 0 | 0 | (373K) |
| Common Stock Issued | 63.98M | 49.84M | 222.36M |
| Common Stock Repurchased | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 |
| Other Financing Activities | (230K) | (423K) | (1.22M) |
| Financing Cash Flow | 63.75M | 49.42M | 220.76M |
| Effect of Forex Changes | 43.67M | (1) | (1.21M) |
| Net Change in Cash | 29.02M | (12.77M) | 27.81M |
| Free Cash Flow | (30.09M) | (58.28M) | (76.68M) |
Evommune, Inc.
NYSE:EVMN
Intrinsic Alpha fair value
Locked
Current Price
$6.88
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.